Hills Bank & Trust Co Purchases 207 Shares of Biogen Inc. (NASDAQ:BIIB)

Hills Bank & Trust Co raised its position in Biogen Inc. (NASDAQ:BIIB) by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,570 shares of the biotechnology company’s stock after acquiring an additional 207 shares during the quarter. Hills Bank & Trust Co’s holdings in Biogen were worth $699,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in BIIB. Larson Financial Group LLC raised its stake in shares of Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after buying an additional 141 shares during the period. OFI Invest Asset Management bought a new position in shares of Biogen in the fourth quarter worth about $32,000. SRS Capital Advisors Inc. bought a new stake in Biogen during the 4th quarter valued at approximately $33,000. Golden State Wealth Management LLC bought a new stake in Biogen during the 4th quarter valued at approximately $41,000. Finally, Venturi Wealth Management LLC raised its stake in Biogen by 73.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 93 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Down 0.4 %

NASDAQ:BIIB opened at $139.44 on Friday. The company has a market cap of $20.41 billion, a price-to-earnings ratio of 12.46, a price-to-earnings-growth ratio of 1.51 and a beta of 0.01. Biogen Inc. has a twelve month low of $128.51 and a twelve month high of $238.00. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The stock has a fifty day simple moving average of $143.09 and a 200-day simple moving average of $164.30.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. Analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on BIIB. HC Wainwright decreased their target price on Biogen from $300.00 to $241.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Bank of America reissued a “neutral” rating and set a $178.00 target price on shares of Biogen in a research note on Tuesday, December 10th. Sanford C. Bernstein began coverage on Biogen in a research note on Tuesday, February 11th. They set a “market perform” rating and a $160.00 target price on the stock. Piper Sandler reissued a “neutral” rating and set a $135.00 target price (down previously from $138.00) on shares of Biogen in a research note on Tuesday, February 18th. Finally, Truist Financial decreased their target price on Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Seventeen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Biogen presently has an average rating of “Hold” and an average target price of $213.33.

Insider Transactions at Biogen

In other news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.